The U.S. Food and Drug Administration announced on February 6, 2026 that it would take enforcement action to stop the mass‑marketing of unapproved compounded semaglutide pills, citing Hims & Hers’ $49 introductory price for its Wegovy copy as a primary example. The agency’s statement warned that the company would be referred to the Department of Justice and that it would restrict access to the drug’s active ingredients, effectively halting the product’s distribution.
Hims & Hers launched its compounded semaglutide pill on February 5, 2026, positioning it as a low‑cost alternative to Novo Nordisk’s approved Wegovy. The company’s $49 first‑month price was intended to undercut the $1,200‑plus price of the FDA‑approved oral formulation. Novo Nordisk filed a formal complaint the same day, accusing Hims & Hers of illegal mass compounding and deceptive marketing practices that could mislead patients and prescribers.
Novo Nordisk’s oral Wegovy relies on proprietary SNAC (salcaprozate sodium) technology, which it acquired when it purchased Emisphere Technologies in 2020 for $1.8 billion. SNAC protects semaglutide from stomach degradation and enhances absorption, a capability that compounded versions lack. CEO Mike Doustdar dismissed the Hims & Hers product as a “waste of $49,” underscoring the company’s belief that the proprietary technology is essential for therapeutic efficacy.
The FDA announcement triggered a sharp market reaction: Novo Nordisk’s shares rose more than 7% after the statement, while Hims & Hers’ stock fell 14% in after‑hours trading. Analysts cited the enforcement as a decisive signal that the FDA would defend approved GLP‑1 drugs, restoring confidence among prescribers and payers who had been wary of compounded alternatives.
For Novo Nordisk, the action removes a low‑cost competitor that had been eroding its pricing power in the U.S. weight‑loss market. By curbing the availability of the compounded pill, the FDA protects Novo’s brand integrity and the value of its SNAC‑based formulation, potentially deterring other telehealth platforms from offering similar products. The enforcement also signals to the market that the agency will actively defend approved drugs, which could help maintain Novo’s market share and pricing strategy in the coming months.
Hims & Hers has not yet issued a formal response to the FDA’s announcement. The company’s future strategy will likely involve either pivoting to a different product line or challenging the enforcement through legal channels, but the current regulatory stance poses a significant headwind to its low‑cost business model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.